Navigation Links
FDA Approves 3 New Drugs for Type 2 Diabetes
Date:1/28/2013

FRIDAY, Jan. 25 (HealthDay News) -- The U.S. Food and Drug Administration late Friday approved three new medications to help people battle type 2 diabetes.

All three drugs contain a new active ingredient, alogliptin, either alone or in combination with other, previously approved medications. The newly approved drugs include Nesina (alogliptin), Kazano (alogliptin plus metformin) and Oseni (alogliptin plus pioglitazone), the FDA said in a news release.

"Controlling blood sugar levels is very important in the overall treatment and care of diabetes," Dr. Mary Parks, director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, said in the statement. "Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control."

More than 24 million people in the United States are currently affected by type 2 diabetes, which is closely linked with obesity. In the type 2 form of the disease, people gradually develop resistance to insulin or fail to produce enough of the hormone, resulting in rising blood sugar levels. That can lead to other health problems, such as heart disease, vision problems and neural or kidney dysfunction.

The FDA urges that the new medications be used in combination with a healthy diet and exercise to help bring diabetes under control. All of the drugs underwent study either as stand-alone products or used alongside standard diabetes medications such as sulfonyureas or insulin.

In the case of Nesina, the drug showed safety and effectiveness across 14 clinical trials, involving more than 8,500 patients, according to the FDA. The most common side effects included stuffy or runny nose, headache, and upper respiratory tract infections.

Kazano's safety and effectiveness were tested in four clinical trials involving more than 2,500 patients. Side effects included those seen with Nesina, as well as diarrhea, high blood pressure and back pain, the FDA said. The agency is also requesting that a "boxed warning" be included on Kazano's labeling, highlighting the potential risk of lactic acidosis (lactic acid buildup in the blood), which can occur in products containing metformin.

Oseni was studied in four clinical trials involving more than 1,500 patients, the FDA noted. Side effects were similar to those seen with Nesina, as well as back pain. Oseni's labeling will also carry a boxed warning, this time cautioning users about the risk for heart failure that accompanies drugs containing pioglitazone.

The drugs will also be subject to what are known as "post-marketing studies," aimed at spotting any emerging risks. For example, studies looking at heart and liver issues are mandated for Nesina, while studies focused on potential liver and pancreas problems are mandated for both Kazano and Oseni, the FDA said.

All three drugs are distributed by Takeda Pharmaceuticals America Inc., of Deerfield, Ill.

More information

Find out more about type 2 diabetes at the American Diabetes Association.

-- E.J. Mundell

SOURCE: Jan. 25, 2013, news release, U.S. Food and Drug Administration


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves 1st Skin Patch to Combat Migraines
2. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
3. FDA Approves New Type of Flu Vaccine
4. FDA Approves New Once-a-Day HIV Pill
5. FDA Approves Flu Vaccine for Coming Season
6. FDA Approves 2nd New Weight-Loss Drug
7. FDA Approves 1st Pill to Help Prevent HIV Infection
8. FDA Approves First New Weight-Loss Drug in More Than a Decade
9. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
10. FDA Approves Combo Shot for Meningitis, Hib in Kids
11. FDA Approves Generic Versions of Plavix
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves 3 New Drugs for Type 2 Diabetes
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... The ... MSC Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... performing North American travel partners for the year based on overall business growth in ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... announced that it has officially formed a distribution partnership with Byers Scientific ... industrial odor management industry. , Through the agreement, OMI Industries formulated a special ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing solutions to critical ... from the Frank Hawkins Kenan Institute of Private Enterprise at the ... policy makers identified concrete solutions at the “What’s Next, America?” conference at the ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January 23, ... Kleyne, the nation’s foremost water advocate and host of the nationally syndicated The ... Voice America, once again welcomed one of her favorite guests and colleagues, Dr. ...
(Date:1/24/2017)... ... ... “Speaking With God’s Voice”: a resolute and spirited call for anointed preaching ... A. Miraglia, a born-again believer, who spent his years teaching high school and Sunday-school, ... “There is little doubt that God Himself prepared me for this study, and God’s ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... NEW YORK , January 24, 2017 ... of the fastest growing industries in the United ... for medicinal use in 2016. In addition, Proposition 64, the ... 57.13% for and 42.87% against on November 8, 2016. This ... are allowed to use and to grow a certain amount ...
(Date:1/24/2017)... , January 24, 2017 ... value of USD 3.8 billion by 2025, according to ... market growth can be attributed to the rising initiatives ... early diagnosis of micro calcifications in breast tissue. Some ... CDC, and Breast Cancer Organization are promoting the early ...
(Date:1/24/2017)... -- Aptuit, LLC, hat heute den Beginn ... General Hospital (MGH) unter Leitung von Dr. Laurence ... und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit erhofft ... Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
Breaking Medicine Technology: